Loading page content…
Loading page content…
3 matching contracts · Updated daily · Contracts Finder + Find a Tender Service
Genomics England, in partnership with the NHS and other stakeholders, is co-designing and delivering a national research study, the Generation Study, involving up to 100,000 newborns to understand the role of whole genome sequencing (WGS) to achieve more timely diagnosis of rare conditions and access to early intervention, enabling faster and better care for babies born with rare childhood onset diseases. The Generation Study aims to assess the benefits, challenges, and feasibility of integrating whole genome sequencing into newborn screening to enhance the early diagnosis and treatment of rare genetic conditions. If successful, the study could establish the foundation for the world's first national newborn screening program incorporating whole genome sequencing. The study also aims to understand how, with consent, newborns' genomic and health data could be used for research to enable new diagnostic discoveries and treatments to be developed. As part of the consent to the study mothers are asked for permission to retain the baby's data and sample and link it to clinical data over the course of their life and the ability to recontact them with further research opportunities. The study will provide an invaluable dataset to researchers across industry and academia, and we have the opportunity to conduct further studies in a subset of these families to maximise the future impact to patients, researchers and the NHS. Deepening our dataset, including by introducing new modalities, is a priority for industry. To do this, we to plan to develop an enhanced longitudinal birth cohort (Babies in Focus) in a subset of participants in the next five years. This will begin with conducting long-read whole genome sequencing of at least 1,000 samples across one or more long read technologies. We are therefore engaging with the market to assess options to partner with a supplier to deliver 1,000 long-read sequences, with potential scope to deliver more.
Value undisclosed
This procurement is for Enterprise ITSM tooling and licences and CMDB tooling and licences, including service design, delivery/project management, implementation, and data migration support. Genomics England is exploring the Enterprise ITSM and does not currently have a configuration management data base (CMDB), which is a fundamental piece of functionality. We are seeking proposals for CMDB solutions which will be used to maintain, monitor, and obtain a better view of our environment. The solution will provide details of the machines on the network, software they're running, and expiry dates, and then link back to our contracts to provide asset numbers of kit etc. Software, licensing, and support will need to be procured to meet this project's needs.
Value undisclosed
Genomics England is a company wholly owned and funded by the Department for Health & Social Care. GEL's vision is a world where everyone benefits from genomic healthcare. Where genomic data and research are translated rapidly into clinical interpretations, insights, and actions, driving better patient outcomes and lower healthcare costs. To capitalise on the opportunities within the genomic healthcare sector, and to support the delivery of the government's strategy over the next several years, GEL will be developing its services to increase its value offering and keep pace within rapidly growing biotech and life science sectors. Delivering our aims will involve multiple projects and programmes focused on making improvements in different areas. GEL's internal expertise will not always be sufficient to realise the required outcomes therefore GEL will draw on external partners with the necessary expertise and capacity to support delivery by establishing a framework of partners to supply the following types of services: Data services Bioengineering services Engineering services IT strategy and architecture services Management services Additional specialist technology and healthcare resources This Prior Information Notice is issued to notify all interested potential partners of a potential procurement to establish a framework agreement in line with Regulation 33 of the Public Contracts Regulations 2015. It is envisaged that the framework would be in place for a minimum of 2 years (potentially up to 4 years). The framework will encompass Research and Healthcare Resource providers to deliver technology outcome-based projects. The framework will have multiple supplier partners and have a number of different Lots. Suppliers will be able to bid for one or multiple Lots either as a single entity or in collaboration with other organisations. This is not a call for competition and a further Contract Notice will be issued to begin a formal procurement procedure. Interested suppliers are invited to view more information regarding the opportunity and respond to our Market Consultation Document. You may need to register on Bravo if you have not already done so: https://public.bravosolution.co.uk/genomicsengland/web/login.html . Once registered, please search for the project under code project_846 A market consultation event will be held on 18 April 2023 and suppliers registered on the e-tendering portal will be contacted with more information regarding this.
£50,000,000
Contract value